PMID- 22079859
OWN - NLM
STAT- MEDLINE
DCOM- 20120503
LR  - 20161125
IS  - 1873-5487 (Electronic)
IS  - 0188-4409 (Linking)
VI  - 42
IP  - 7
DP  - 2011 Oct
TI  - Prognostic value of elevated SHIP2 expression in laryngeal squamous cell 
      carcinoma.
PG  - 589-95
LID - 10.1016/j.arcmed.2011.10.012 [doi]
AB  - BACKGROUND AND AIMS: SHIP2, an important negative regulator of insulin signaling, 
      has recently been found to be involved in cancer development and progression. 
      METHODS: In this study, immunohistochemistry was performed to investigate SHIP2 
      expression in laryngeal squamous cell carcinoma (LSCC) clinical samples. 
      Additionally, the relationship of SHIP2 expression to clinicopathological 
      parameters and prognosis was investigated. RESULTS: SHIP2 expression was detected 
      in 42 (42/54, 77.8%) primary tumor samples but only in three (3/16, 18.75%) 
      adjacent normal samples (p <0.001). Moreover, SHIP2 expression was closely 
      associated with T classification (p = 0.006), clinical stage (I + II/III + IV) 
      (p = 0.001), metastasis (p = 0.002) and recurrence (p = 0.004). Survival analysis 
      revealed that high SHIP2 expression was significantly associated with shorter 
      disease-free and overall survival (both p <0.001). When lymph node status and 
      SHIP2 expression were combined, lymph node-positive patients with SHIP2 
      overexpression had both poorer disease-free and overall survival than the others 
      (both p <0.001). Multivariate analysis further demonstrated that SHIP2 was an 
      independent prognostic factor for patients with LSCC. CONCLUSIONS: Collectively, 
      these results support the hypothesis that SHIP2 may play a critical role in the 
      initiation and progression of LSCC and may serve as both a prognostic marker and 
      a potential therapeutic target in patients with LSCC.
CI  - Copyright (c) 2011 IMSS. Published by Elsevier Inc. All rights reserved.
FAU - Zhou, Xiaojuan
AU  - Zhou X
AD  - Department of Otolaryngology-Head and Neck Surgery, Third Xiangya Hospital, 
      Central South University, Changsha, Hunan, China.
FAU - Liu, Yong
AU  - Liu Y
FAU - Tan, Guolin
AU  - Tan G
LA  - eng
PT  - Journal Article
DEP - 20111108
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
RN  - EC 3.1.3.86 (INPPL1 protein, human)
RN  - EC 3.1.3.86 (Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases)
SB  - IM
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases
MH  - Phosphoric Monoester Hydrolases/*metabolism
MH  - Prognosis
MH  - Recurrence
EDAT- 2011/11/15 06:00
MHDA- 2012/05/04 06:00
CRDT- 2011/11/15 06:00
PHST- 2011/07/06 00:00 [received]
PHST- 2011/10/20 00:00 [accepted]
PHST- 2011/11/15 06:00 [entrez]
PHST- 2011/11/15 06:00 [pubmed]
PHST- 2012/05/04 06:00 [medline]
AID - S0188-4409(11)00215-3 [pii]
AID - 10.1016/j.arcmed.2011.10.012 [doi]
PST - ppublish
SO  - Arch Med Res. 2011 Oct;42(7):589-95. doi: 10.1016/j.arcmed.2011.10.012. Epub 2011 
      Nov 8.